Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex–haplo-identical non-myeloablative hematopoietic cell transplantation

References

• Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance [erratum appears in Immunol Rev. 2004;197:243]. Immunol Rev. 2003;196:85–108.
   PubMed Web of Science ®Google Scholar
• McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev. 1998;165:231–47.
   PubMed Web of Science ®Google Scholar
• Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992; 356:607–9.
   PubMed Web of Science ®Google Scholar
• Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei RQ, . T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA. 1992;89:11102–5.
   PubMed Web of Science ®Google Scholar
• Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991;174:561–9.
   PubMed Web of Science ®Google Scholar
• Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, . CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995;155:4521–4.
   PubMed Web of Science ®Google Scholar
• Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol. 1999;162:1947–51.
   PubMed Web of Science ®Google Scholar
• Loughran TP Jr, Deeg HJ, Storb R. Morphologic and phenotypic analysis of canine natural killer cells: evidence for T-cell lineage. Cell Immunol. 1985;95:207–17.
   PubMedGoogle Scholar
• Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, . Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science. 1992; 257:789–92.
   PubMed Web of Science ®Google Scholar
• Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, . Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med. 1993;178:1801–6.
   PubMed Web of Science ®Google Scholar
• Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4-Ig. Transplantation. 1994;57:1701–6.
   PubMed Web of Science ®Google Scholar
• Wallace PM, Johnson JS, Macmaster JF, Kennedy KA, Gladstone P, Linsley PS. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. Transplantation. 1994;58: 602–10.
   PubMed Web of Science ®Google Scholar
• Yin DP, Sankary HN, Williams J, Krieger N, Fathman CG. Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig. Transplantation. 1996;62:1537–9.
   PubMed Web of Science ®Google Scholar
• Levisetti MG, Padrid PA, Szot GL, Mittal N, Meehan SM, Wardrip CL, . Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol. 1997;159:5187–91.
   PubMed Web of Science ®Google Scholar
• Shirasugi N, Akiyama Y, Aramaki O, Shibutani S, Matsumoto K, Bashuda H, . Role of the CTLA4 pathway in hyporesponsiveness induced by intratracheal delivery of alloantigen. Transplantation. 2003;75:1636–9.
   Google Scholar
• Foster RD, Pham S, Li S, Aitouche A. Long-term acceptance of composite tissue allografts through mixed chimerism and CD28 blockade. Transplantation. 2003;76:988–94.
   Google Scholar
• Ibrahim S, Jakobs F, Kittur D, Hess A, Linsley PS, Sanfilippo F, . CTLA4Ig inhibits alloantibody responses to repeated blood transfusions. Blood. 1996;88:4594–600.
   PubMedGoogle Scholar
• Speiser DE, Bachmann MF, Shahinian A, Mak TW, Ohashi PS. Acute graft-versus-host disease without costimulation via CD28. Transplantation. 1997;63:1042–4.
   PubMed Web of Science ®Google Scholar
• Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem H-P, . Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048–54.
   PubMed Web of Science ®Google Scholar
• Storb R, Yu C, Zaucha JM, Deeg HJ, Georges G, Kiem H-P, . Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood. 1999;94:2523–9.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Kerbauy FR, Gooley T, Santos EB, Storb R, Sandmaier BM. Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and nonmyeloablative conditioning in a preclinical canine model. Transplantation. 2006;82:332–9.
   Google Scholar
• Sandmaier BM, Storb R, Appelbaum FR, Gallatin WM. An antibody that facilitates hematopoietic engraftment recognizes CD44. Blood. 1990;76:630–5.
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Storb R, Bennett KL, Appelbaum FR, Santos EB. Epitope specificity of CD44 for monoclonal antibody dependent facilitation of marrow engraftment in a canine model. Blood. 1998;91:3494–502.
   Google Scholar
• Tan PHS, Santos EB, Rossbach HC, Sandmaier BM. Enhancement of natural killer activity by an antibody to CD44. J Immunol. 1993;150:812–20.
   PubMed Web of Science ®Google Scholar
• Tan PH, Liu Y, Santos EB, Sandmaier BM. Mechanisms of enhancement of natural killer activity by an antibody to CD44: increase in conjugate formation and release of tumor necrosis factor α. Cell Immunol. 1995;164:255–64.
   PubMed Web of Science ®Google Scholar
• Tan PH, Sandmaier BM, Stayton PS. Characterization of an anti-CD44 single-chain FV antibody that stimulates natural killer cell activity and induces TNFα release. Immunol Invest. 1995;24:907–26.
   PubMed Web of Science ®Google Scholar
• Wagner JL, Burnett RC, DeRose SA, Francisco LV, Storb R, Ostrander EA. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation. 1996;62:876–7.
   Google Scholar
• Wagner JL, Burnett RC, Works JD, Storb R. Molecular analysis of DLA-DRBB1 polymorphism. Tissue Antigens. 1996;48:554–61.
   Google Scholar
• Wagner JL, Works JD, Storb R. DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Tissue Antigens. 1998;52:397–401.
   Google Scholar
• Raff RF, Deeg HJ, Farewell VT, DeRose S, Storb R. The canine major histocompatibility complex. Population study of DLA-D alleles using a panel of homozygous typing cells. Tissue Antigens. 1983;21:360–73.
   Google Scholar
• Storb R, Raff RF, Graham T, Appelbaum FR, Deeg HJ, Schuening FG, . Marrow toxicity of fractionated versus single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys. 1993;26:275–83.
   PubMed Web of Science ®Google Scholar
• Zaucha JM, Zellmer E, Georges G, Little M-T, Storb R, Storer B, . G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biol Blood Marrow Transplant. 2001;7:613–9.
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Storb R, Santos EB, Krizanac-Bengez L, Lian T, McSweeney PA, . Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood. 1996;87:3508–13.
   Google Scholar
• Lee R, Storb R, Little M-T, Joslyn A, Spector M, Kuhr CS. Percutaneous central dual-lumen catheter for apheresis in the canine. J Invest Surg. 2002;15:337–41.
   Web of Science ®Google Scholar
• Deeg HJ, Storb R. Canine marrow transplantation models. Curr Topics Vet Res. 1994;1:103–14.
   Google Scholar
• Ladiges WC, Storb R, Thomas ED. Canine models of bone marrow transplantation. Lab Anim Sci. 1990;40:11–5.
   Google Scholar
• Moore PF, Rossitto PV, Danilenko DM, Wielenga JJ, Raff RF, Severns E. Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high density expression of CD4 by canine neutrophils. Tissue Antigens. 1992;40:75–85.
   PubMed Web of Science ®Google Scholar
• Barsoukov AA, Moore PF, Storb R, Santos EB, Sandmaier BM. The use of an anti-TCRαβ monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation. 1999;67:1329–35.
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Schuening FG, Bianco JA, Rosenman SJ, Bernstein I, Goehle S, . Biochemical characterization of a unique canine myeloid antigen. Leukemia. 1991;5:125–30.
   Google Scholar
• Denkers E, Badger CC, Ledbetter JA, Bernstein ID. Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol. 1985;135:2183–6.
   PubMedGoogle Scholar
• Jacobsen CN, Aasted B, Broe MK, Petersen JL. Reactivities of 20 anti-human monoclonal antibodies with leucocytes from ten different animal species. Vet Immunol Immunopath. 1993;39:461–6.
   PubMed Web of Science ®Google Scholar
• Yu C, Ostrander E, Bryant E, Burnett R, Storb R. Use of (CA)n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting. Transplantation. 1994;58:701–6.
   Google Scholar
• Raff RF, Sandmaier BM, Graham T, Loughran TP Jr, Pettinger M, Storb R. ‘Resistance’ to DLA-nonidentical canine unrelated marrow grafts is unrestricted by the major histocompatibility complex. Exp Hematol. 1994;22:893–7.
   PubMedGoogle Scholar
• Raff RF, Deeg HJ, Loughran TP Jr, Graham TC, Aprile JA, Sale GE, . Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donors. Blood. 1986;68:861–8.
   Google Scholar
• Storb R, Weiden PL, Graham TC, Lerner KG, Nelson N, Thomas ED. Hemopoietic grafts between DLA-identical canine littermates following dimethyl myleran. Evidence for resistance to grafts not associated with DLA and abrogated by antithymocyte serum. Transplantation. 1977;24:349–57.
   PubMedGoogle Scholar
• Srinivas NR, Shyu WC, Weiner RS, Tay LK, Greene DS, Barbhaiya RH. Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice. J Pharm Sci. 1995; 84:1488–9.
   PubMed Web of Science ®Google Scholar
• Srinivas NR, Weiner RS, Warner G, Shyu WC, Davidson T, Fadrowski CG, . Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. J Pharm Sci. 1996;85:1–4.
   PubMed Web of Science ®Google Scholar
• Lundquist L. Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis. Adv Ther. 2007;24:333–45.
   PubMed Web of Science ®Google Scholar
• Storb R, Raff RF, Appelbaum FR, Schuening F, Sandmaier B, Shulman H, . Failure of antithymocyte serum postgrafting to overcome ‘resistance’ to DLA-nonidentical canine marrow grafts. Transplantation. 1988;45:236–9.
   Google Scholar
• Suzue K, Reinherz EL, Koyasu S. Critical role of NK but not NKT cells in acute rejection of parental bone marrow cells in F1 hybrid mice. Eur J Immunol. 2001;31:3147–52.
   Google Scholar
• Larsen CP, Page A, Linzie KH, Russell M, Deane T, Stempora L, . An MHC-defined primate model reveals significant rejection of bone marrow after mixed chimerism induction despite full MHC matching. Am J Transplant. 2010;10: 2396–409.
   Google Scholar
• Montgomery M, Cottler-Fox M. Mobilization and collection of autologous hematopoietic progenitor/stem cells. Clin Adv Hematol Oncol. 2007;5:127–36.
   PubMedGoogle Scholar
• Cashen AF, Nervi B, DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Fut Oncol. 2007;3:19–27.
   PubMedGoogle Scholar
• Thakar MS, Santos EB, Fricker S, Bridger G, Storb R, Sandmaier BM. Plerixafor-mobilized stem cells alone are capable of inducing early engraftment across the MHC–haploidentical canine barrier. Blood. 2010;115:916–7.
   Google Scholar